Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium in Relapsed/Refractory CLL
NCT00076401Phase 2Terminated
- Sponsor
- Pharmacyclics
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of motexafin gadolinium in chronic lymphocytic leukemia (CLL), sponsored by Pharmacyclics. Primary endpoint: Objective Response Rate. Status: terminated.
02
Drugs
motexafin gadolinium
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00076401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076401.